1 141

Cited 19 times in

Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC).

Authors
 Sang Gyu Lee  ;  Young Geon Jee  ;  Hyun Chul Chung  ;  Sung-Bae Kim  ;  Jungsil Ro  ;  Young-Hyuck Im  ;  Seock-Ah Im  ;  Jae Hong Seo 
Citation
 BREAST CANCER RESEARCH AND TREATMENT, Vol.114(3) : 589-595, 2009 
Journal Title
 BREAST CANCER RESEARCH AND TREATMENT 
ISSN
 0167-6806 
Issue Date
2009
MeSH
Adult ; Antineoplastic Combined Chemotherapy Protocols/economics* ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/economics* ; Clinical Trials as Topic/economics ; Cost-Benefit Analysis/economics ; Cyclophosphamide/administration & dosage* ; Cyclophosphamide/therapeutic use ; Disease-Free Survival ; Doxorubicin/administration & dosage* ; Doxorubicin/therapeutic use ; Female ; Fluorouracil/therapeutic use ; Humans ; Korea ; Middle Aged ; Taxoids/administration & dosage* ; Treatment Outcome
Keywords
Adjuvant therapy ; Breast cancer ; Cost–effectiveness ; Taxanes ; Korean
Abstract
BACKGROUND: This study evaluated the incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) of TAC compared with FAC following primary surgery for node positive breast cancer patients in Korea. MATERIALS AND METHODS: A cost-effectiveness analysis was performed using the Markov model from the combined view of Korean National Health Insurance and patients. The model allowed assessment from the beginning of the first cycle of adjuvant chemotherapy following primary surgery until death. Relevant clinical data were obtained from the clinical trial BCIRG 001 and data for local treatment patterns and direct medical costs were obtained from three Korean hospitals. RESULTS: Over a life time horizon, the life expectancy of TAC was 0.9 years longer than that of FAC. The ICER was 8,025,879 Korean won (KW, 6,573 euro) per life year gained and the ICUR was 8,885,794 KW (7,277 euro) per QALY gained when the cost and effectiveness were discounted at 5%. The model was most sensitive to the percent patient receiving prophylactic granulocyte colony stimulating factor (G-CSF) in TAC arm and the ICUR was 12,119,561 KW (9,926 euro) when assuming 100%. CONCLUSIONS: TAC appears to be cost-effective in the management of early breast cancer in Korea.
Full Text
http://link.springer.com/article/10.1007%2Fs10549-008-0035-0
DOI
10.1007/s10549-008-0035-0
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103722
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links